Where can I find CSPCY's financial statements?

CSPC Pharmaceutical Group Limited (CSPCY)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for CSPCY?

CSPC Pharmaceutical Group Limited (CSPCY) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does CSPCY update its statements?

CSPC Pharmaceutical Group Limited files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

CSPCY

CSPC Pharmaceutical Group Limited

OTC·Biotechnology · Healthcare

$4.25$0.16+3.91%

After hours·$4.25+0.00%

Market cap$12.12B·Market closed·Jul 21 7:08 PM UTC

CNY · values shown as reported

Line item	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	¥27.90B+11.9%	¥30.94B+10.9%	¥34.60B+11.8%	¥28.99B−16.2%	¥25.29B−12.8%
Cost of revenue	¥6.73B+7.6%	¥8.68B+28.9%	¥10.20B+17.5%	¥8.71B−14.7%	¥8.70B−0.0%
Gross profit	¥21.14B+13.1%	¥22.26B+5.3%	¥24.40B+9.6%	¥20.29B−16.9%	¥16.59B−18.2%
Research & development	¥3.44B+18.9%	¥4.58B+33.1%	¥5.34B+16.6%	¥5.19B−2.8%	¥5.65B+8.9%
General & administrative	¥1.01B+27.1%	¥1.33B+31.3%	¥1.31B−1.4%	¥1.08B−17.6%	¥825.46M−23.5%
Selling & marketing	¥10.46B+11.5%	¥11.70B+11.9%	¥10.06B−14.0%	¥8.66B−13.9%	¥6.46B−25.3%
SG&A (combined)	¥11.47B+32.0%	¥13.03B+13.6%	¥11.36B−12.8%	¥9.74B−14.3%	¥7.29B−25.1%
Other operating expenses	—	−¥2.11B	¥14.95M+100.7%	—	−¥210.45M
Total operating expenses	¥14.91B+12.9%	¥15.50B+4.0%	¥16.72B+7.9%	¥14.92B−10.7%	¥12.73B−14.7%
Operating income	¥6.25B+14.5%	¥6.91B+10.5%	¥7.68B+11.2%	¥5.43B−29.3%	¥3.86B−28.9%
Interest income	—	—	—	—	¥190.48M
Interest expense	¥6.25M−39.2%	¥24.89M+298.0%	¥25.90M+4.0%	¥41.02M+58.4%	¥37.53M−8.5%
Other income / (expense), net	¥601.60M−34.8%	¥808.73M+34.4%	−¥290.75M−136.0%	¥212.45M+173.1%	¥814.06M+283.2%
Income before tax	¥6.85B+7.3%	¥7.72B+12.6%	¥7.39B−4.2%	¥5.58B−24.6%	¥4.68B−16.1%
Income tax expense	¥1.16B−0.1%	¥1.35B+16.4%	¥1.32B−2.5%	¥1.24B−5.9%	¥906.07M−26.9%
Net income	¥5.61B+29.3%	¥6.20B+10.5%	¥5.87B−5.2%	¥4.33B−26.4%	¥3.78B−12.7%

EPS (basic)	¥1.88+14.6%	¥2.04+8.5%	¥2.00−2.0%	¥1.48−26.0%	¥1.32−10.8%
EPS (diluted)	¥1.88+14.6%	¥2.04+8.5%	¥2.00−2.0%	¥1.48−26.0%	¥1.32−10.8%
Weighted avg shares (basic)	2,988,371,500	2,979,301,000	2,968,124,500	2,934,667,000	2,855,923,000
Weighted avg shares (diluted)	2,988,459,750	2,979,630,750	2,968,257,750	2,934,510,750	2,855,923,000

Depreciation & amortization	¥849.47M+5.0%	¥1.05B+23.4%	¥1.12B+6.6%	¥1.08B−3.0%	¥1.37B+26.4%
EBITDA	¥7.02B−2.7%	¥8.66B+23.3%	¥8.53B−1.4%	¥6.45B−24.4%	¥5.23B−18.8%

Frequently Asked Questions About CSPCY

Where can I find CSPCY's financial statements?: CSPC Pharmaceutical Group Limited (CSPCY)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for CSPCY?: CSPC Pharmaceutical Group Limited (CSPCY) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does CSPCY update its statements?: CSPC Pharmaceutical Group Limited files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Trend

Revenue

¥27.90B+11.9%

¥30.94B+10.9%

¥34.60B+11.8%

¥28.99B−16.2%

¥25.29B−12.8%

Cost of revenue

¥6.73B+7.6%

¥8.68B+28.9%

¥10.20B+17.5%

¥8.71B−14.7%

¥8.70B−0.0%

Gross profit

¥21.14B+13.1%

¥22.26B+5.3%

¥24.40B+9.6%

¥20.29B−16.9%

¥16.59B−18.2%

Research & development

¥3.44B+18.9%

¥4.58B+33.1%

¥5.34B+16.6%

¥5.19B−2.8%

¥5.65B+8.9%

General & administrative

¥1.01B+27.1%

¥1.33B+31.3%

¥1.31B−1.4%

¥1.08B−17.6%

¥825.46M−23.5%

Selling & marketing

¥10.46B+11.5%

¥11.70B+11.9%

¥10.06B−14.0%

¥8.66B−13.9%

¥6.46B−25.3%

SG&A (combined)

¥11.47B+32.0%

¥13.03B+13.6%

¥11.36B−12.8%

¥9.74B−14.3%

¥7.29B−25.1%

Other operating expenses

—

−¥2.11B

¥14.95M+100.7%

—

−¥210.45M

Total operating expenses

¥14.91B+12.9%

¥15.50B+4.0%

¥16.72B+7.9%

¥14.92B−10.7%

¥12.73B−14.7%

Operating income

¥6.25B+14.5%

¥6.91B+10.5%

¥7.68B+11.2%

¥5.43B−29.3%

¥3.86B−28.9%

Interest income

—

¥190.48M

Interest expense

¥6.25M−39.2%

¥24.89M+298.0%

¥25.90M+4.0%

¥41.02M+58.4%

¥37.53M−8.5%

Other income / (expense), net

¥601.60M−34.8%

¥808.73M+34.4%

−¥290.75M−136.0%

¥212.45M+173.1%

¥814.06M+283.2%

Income before tax

¥6.85B+7.3%

¥7.72B+12.6%

¥7.39B−4.2%

¥5.58B−24.6%

¥4.68B−16.1%

Income tax expense

¥1.16B−0.1%

¥1.35B+16.4%

¥1.32B−2.5%

¥1.24B−5.9%

¥906.07M−26.9%

Net income

¥5.61B+29.3%

¥6.20B+10.5%

¥5.87B−5.2%

¥4.33B−26.4%

¥3.78B−12.7%

EPS (basic)

¥1.88+14.6%

¥2.04+8.5%

¥2.00−2.0%

¥1.48−26.0%

¥1.32−10.8%

EPS (diluted)

¥1.88+14.6%

¥2.04+8.5%

¥2.00−2.0%

¥1.48−26.0%

¥1.32−10.8%

Weighted avg shares (basic)

2,988,371,500

2,979,301,000

2,968,124,500

2,934,667,000

2,855,923,000

Weighted avg shares (diluted)

2,988,459,750

2,979,630,750

2,968,257,750

2,934,510,750

2,855,923,000

Depreciation & amortization

¥849.47M+5.0%

¥1.05B+23.4%

¥1.12B+6.6%

¥1.08B−3.0%

¥1.37B+26.4%

EBITDA

¥7.02B−2.7%

¥8.66B+23.3%

¥8.53B−1.4%

¥6.45B−24.4%

¥5.23B−18.8%